Inclusion Criteria:

- Patients must have had first menses <= 6 months prior to enrollment

- Patients must be newly diagnosed with lymphoma. This includes but is not limited to
Hodgkin Lymphoma, Burkitts Lymphoma, Diffuse Large B Cell Lymphoma, and Anaplastic
Large Cell Lymphoma.

- Planned cancer treatment must include an alkylating agent: ie procarbazine,
cyclophosphamide, ifosphamide. Planned cancer treatment must be less than one year.

- Patients with any performance status are eligible for enrollment

- Patients may take oral contraceptives

Exclusion Criteria:

- Patients who have previously received chemotherapy other than steroids

- Patients who have a secondary malignancy are not eligible

- Patients with known history of ovarian disease: e.g. Turner Syndrome or Polycystic
Ovarian Syndrome

- Patients in whom planned therapy includes: removal or uterus or ovary(ies), pelvic
irradiation, cranial irradiation or hematopoietic stem cell transplantation are not
eligible

- Patients who previously have had their uterus or ovary(ies) removed are not eligible

- Patients who have received gonadotropin release hormone agonist or antagonist (e.g.
Lupron) prior to study entry are not eligible

- Patients who are pregnant or breast feeding are not eligible

- Patients who have undergone or are planning to undergo ovarian tissue, oocyte or
embryo cryopreservation prior to treatment are not eligible